Clinical TrialMay 6, 2026, 08:41 AM
InflaRx Advances Izicopan for ANCA-Associated Vasculitis & Renal Diseases
AI Summary
InflaRx N.V. announced its intention to develop izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis (AAV) and other life-threatening renal diseases including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G). The company is planning Phase 2 for AAV and open-label studies for other renal indications, with clinical data expected next year. InflaRx estimates it has sufficient funds for planned clinical development and operations through 2029. A Capital Markets Day is scheduled for summer 2026 to detail izicopan's potential.
Key Highlights
- InflaRx intends to develop izicopan for ANCA-associated vasculitis (AAV) and select renal diseases.
- Phase 2 planning for izicopan in AAV is underway, exploring an expedited path to market.
- Open-label studies for atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G) are expected to generate clinical data next year.
- InflaRx estimates sufficient funds for planned clinical development and operations through 2029.
- Izicopan is an oral C5aR inhibitor with potential best-in-class properties, including improved safety and dosing.
- A Capital Markets Day is planned for summer 2026 to detail izicopan's potential in AAV and renal disorders.
- The market for C5aR inhibitors in AAV is estimated at ~$1.3 billion.
Price Impact
More from IFRX